Corcept Therapeutics Inc CORT
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. 10-K, Item 1
- Headquarters
- Redwood City, CA
- CEO
- Joseph K. Belanoff
- Next results
- around Feb 23, 2027
Where each dollar of revenue went, FY2025
Revenue of $761.4M through the costs to a net profit of $99.7M · income statement of the 10-K
CORT among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
29 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 26, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 11 checks found nothing to note
-
Receivables +10.8% ($54.0M to $59.8M) vs revenue +12.8% ($675.0M to $761.4M), -2.0 pts apart
-
Cash from operations $142.0M vs net income $99.7M (FY ending Dec 31, 2025)
-
Inventory +3.7% ($12.4M to $12.9M) vs revenue +12.8% ($675.0M to $761.4M), -9.1 pts apart
8 more checks with nothing to note
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Net Product Revenue - Accounting for Government Rebates
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
29 paragraphs in Risk Factors that were not in the 10-K filed Feb 26, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at the HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
We do not currently have nor do we have immediate plans to acquire the infrastructure or internal capability to manufacture our clinical drug supplies for use in the conduct of our clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. The…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
We cannot sell a product without the approval of the FDA, EMA or comparable regulatory authority. Obtaining such approval is difficult, uncertain, lengthy and expensive. Failure can occur at any stage. In order to receive FDA approval for a new drug, we must demonstrate to the FDA’s satisfaction that the new drug is safe and effective…
-
Item 1A · new paragraph · not in the 10-K filed Feb 26, 2025 10-K, ITEM 1A
We submitted an NDA for relacorilant as a treatment for patients with hypercortisolism. On December 30, 2025, the FDA issued a CRL declining to approve relacorilant for the proposed use and stating that additional evidence of effectiveness was required. We plan to meet with the FDA to arrive at the best path to approval. We have also…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $401.9M | $482.4M | $675.0M | $761.4M |
| Net income | $101.4M | $106.1M | $141.2M | $99.7M |
| Operating cash flow | $120.3M | $126.7M | $198.3M | $142.0M |
| Free cash flow | $119.9M | $126.5M | $196.1M | $141.8M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$761.4M ▲ 12.8% in FY2025$99.7M ▼ 29.4% in FY2025$141.8M ▼ 27.7% in FY2025
Recent filings
7 filings in the last 30 days · SEC EDGAR
-
SEC letterNov 14, 2026SEC asked 2 questions letters Sep 12, 2017 to Sep 25, 2017 · Revenue, Results discussion (MD&A)
-
Planned saleNov 10, 2026DANIEL SWISHER JR. (Director) gave notice of a planned sale of 1,500 shares worth about $113K Form 144, approximate sale date Nov 10, 2026, under a 10b5-1 plan adopted Aug 3, 2026
-
Planned saleNov 3, 2026Daniel N. Swisher, Jr. (Director) adopted a 10b5-1 trading plan reported in the 10-Q, up to 180,000 shares, runs to Oct 31, 2027
-
Planned saleNov 3, 2026Atabak Mokari (Chief Financial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 200,000 shares, runs to Nov 14, 2027
-
Planned saleNov 3, 2026William Guyer (Chief Development Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 360,000 shares, runs to May 31, 2028
About the company
Corcept Therapeutics Inc, Redwood City, CA · from the 10-K filed Feb 24, 2026
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day. Insufficient cortisol activity may lead to dehydration, hypotension, shock, fatigue and hypoglycemia.
- Headquarters
- Redwood City, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 26, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CORT/export.csv") into a cell.